GU Cancers 2023 | A retrospective study on the safety and efficacy of ICIs in advanced penile cancer

Talal El Zarif, MD, Dana-Farber Cancer Institute, Boston, MA, shares the results of a retrospective study conducted by the Global Society of Rare Genitourinary Tumors on the safety and efficacy of immune checkpoint inhibitors (ICIs) in patients with advanced penile cancer. 92 patients were included. The median overall-survival (OS) was 9.8 months in the overall cohort and the median progression-free survival (PFS) was 3.2 months, with an overall response rate (ORR) of 13%. 29% of patients experienced adverse events of any grade. For patients receiving ICI monotherapy, the incidence of adverse events was 21%, increasing to 31% with combination treatment of anti-PD1 and anti-CTLA-4 and 75% with the addition of a TKI. This interview took place at the ASCO GU Cancers Symposium 2023 in San Francisco, CA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.